Press release
Uveitis Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight
"Uveitis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uveitis Market.
The Uveitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Uveitis Pipeline Report: https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Uveitis treatment therapies with a considerable amount of success over the years.
• Uveitis companies working in the treatment market are Clearside Biomedical, Bausch+Lomb, EyePoint Pharmaceuticals, Alimera Sciences, Tarsier Pharma, Oculis Pharma, Eli Lilly and Company, VivaVision Biotech, Inc, Chugai Pharmaceutical, Priovant Therapeutics, Inc., ACELYRIN Inc., Bio-Thera Solutions, Eli Lilly and Company, Massachusetts Eye Research, Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others, are developing therapies for the Uveitis treatment
• Emerging Uveitis therapies in the different phases of clinical trials are- XIPERE, YUTIQ, ILUVIEN, TRS01, OCS-02 (licaminlimab), Barcitinib, VVN461, RAY 121, Brepocitinib PO QD, Izokibep, QLETLI, Baricitinib, Ixekizumab Prefilled Syringe, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others are expected to have a significant impact on the Uveitis market in the coming years.
• Emerging therapies TRS01, licaminlimab (OCS-02), and vamikibart (RO720220/ RG6179) can potentially create a positive shift in the uveitis market size during the forecast period.
• If it receives approval, Tarsier Pharma's TRS01 could become the first nonsteroidal eye drop therapy for noninfectious anterior uveitis.
• OCS-02 is a single-chain antibody fragment that offers both anti-inflammatory and anti-necrotic effects. It aims to meet the critical need for a steroid-sparing therapy and a topical biologic option without the systemic safety concerns.
• Roche's RG6179, a humanized recombinant antibody designed to inhibit IL-6 signaling, targets uveitic macular edema. The therapy is projected to launch in the US by 2026.
• In September 2024, Priovant Therapeutics has announced the enrollment of the first patients in CLARITY, a Phase 3 study investigating brepocitinib for non-anterior non-infectious uveitis (NIU). Additionally, brepocitinib has received Fast Track Designation from the FDA for NIU. The Fast Track process is aimed at accelerating the development and review of drugs that address serious conditions and unmet medical needs.
• In April 2024, Roivant and Priovant Therapeutics announced positive results from the Phase II NEPTUNE clinical trial of brepocitinib for non-anterior non-infectious uveitis (NIU). The double-blind trial included 26 participants with active NIU, who were randomized in a 2:1 ratio to receive either 45mg or 15mg of brepocitinib daily. The study also included an initial prednisone burst of 60mg per day for two weeks, followed by a six-week tapering period.
• In January 2024, Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company specializing in first-in-class therapies for blinding ocular diseases, announced that it has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA). This agreement pertains to the clinical trial protocol and planned statistical analysis for the Tarsier-04 Phase 3 trial, which will evaluate TRS01 eye drops for treating non-infectious uveitis, including uveitic glaucoma.
Uveitis Overview
Uveitis is an inflammation of the uvea, the middle layer of the eye that includes the iris, ciliary body, and choroid. It can be caused by infections, autoimmune disorders, or injuries, and can lead to symptoms like eye redness, pain, blurred vision, light sensitivity, and floaters. If left untreated, uveitis can result in serious complications, such as glaucoma, cataracts, or even vision loss. Treatment typically involves anti-inflammatory medications like corticosteroids, and in some cases, immunosuppressive drugs or biologics may be used depending on the underlying cause. Regular eye exams are important for early detection and management.
Get a Free Sample PDF Report to know more about Uveitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Uveitis Drugs Under Different Phases of Clinical Development Include:
• XIPERE: Clearside Biomedical/Bausch+Lomb
• YUTIQ/ILUVIEN: EyePoint Pharmaceuticals/Alimera Sciences
• TRS01: Tarsier Pharma
• OCS-02 (licaminlimab): Oculis Pharma
• Barcitinib: Eli Lilly and Company
• VVN461: VivaVision Biotech, Inc
• RAY 121: Chugai Pharmaceutical
• Brepocitinib PO QD: Priovant Therapeutics, Inc.
• Izokibep: ACELYRIN Inc.
• QLETLI: Bio-Thera Solutions
• Baricitinib: Eli Lilly and Company
• Ixekizumab Prefilled Syringe: Massachusetts Eye Research
• ESK-001: Alumis Inc
• OCS-01: Quan Dong Nguyen
• Dusquetide: Soligenix
• Hemay005: Ganzhou Hemay Pharmaceutical
• Apremilast: Amgen
Uveitis Route of Administration
Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Uveitis Molecule Type
Uveitis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Uveitis Pipeline Therapeutics Assessment
• Uveitis Assessment by Product Type
• Uveitis By Stage and Product Type
• Uveitis Assessment by Route of Administration
• Uveitis By Stage and Route of Administration
• Uveitis Assessment by Molecule Type
• Uveitis by Stage and Molecule Type
DelveInsight's Uveitis Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Uveitis product details are provided in the report. Download the Uveitis pipeline report to learn more about the emerging Uveitis therapies
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Uveitis Therapeutics Market include:
Key companies developing therapies for Uveitis are - AbbVie Inc., Novartis AG, Allergan Inc., Bausch & Lomb Incorporated, Santen Pharmaceutical Co. Ltd, Eyegate Pharmaceuticals Inc., Regeneron Pharmaceuticals, Eyepoint Pharmaceuticals Inc., Alimera Sciences Inc., and others.
Uveitis Pipeline Analysis:
The Uveitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Uveitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uveitis Treatment.
• Uveitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uveitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uveitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Uveitis drugs and therapies
https://www.delveinsight.com/sample-request/uveitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Uveitis Pipeline Market Strengths
• The remarkable advances in ocular immunology over the past decades have led to a better understanding of the molecular mechanisms that underlie etiology and susceptibility to uveitis
• New drugs with diverse mechanisms of action and routes of administration have been approved in the recent past, improving the treatment regime
Uveitis Pipeline Market Opportunities
• Opportunity for companies to implement knowledge from recent advances in understanding the etiologies associated with uveitis to evaluate potential drugs with novel targets
• Biomarker discovery and proteomics provide potential targets for therapeutic intervention by the drugs that are available and accessible, besides providing information about the drug that can be avoided
Scope of Uveitis Pipeline Drug Insight
• Coverage: Global
• Key Uveitis Companies: Clearside Biomedical, Bausch+Lomb, EyePoint Pharmaceuticals, Alimera Sciences, Tarsier Pharma, Oculis Pharma, Eli Lilly and Company, VivaVision Biotech, Inc, Chugai Pharmaceutical, Priovant Therapeutics, Inc., ACELYRIN Inc., Bio-Thera Solutions, Eli Lilly and Company, Massachusetts Eye Research, Alumis Inc, Quan Dong Nguyen, Soligenix, Ganzhou Hemay Pharmaceutical, Amgen, and others
• Key Uveitis Therapies: XIPERE, YUTIQ, ILUVIEN, TRS01, OCS-02 (licaminlimab), Barcitinib, VVN461, RAY 121, Brepocitinib PO QD, Izokibep, QLETLI, Baricitinib, Ixekizumab Prefilled Syringe, ESK-001, OCS-01, Dusquetide, Hemay005, Apremilast, and others
• Uveitis Therapeutic Assessment: Uveitis current marketed and Uveitis emerging therapies
• Uveitis Market Dynamics: Uveitis market drivers and Uveitis market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveitis Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight here
News-ID: 4305700 • Views: …
More Releases from DelveInsight Business Research
Aplastic Anemia Market Expected to Experience Major Growth by 2034, According to …
DelveInsight's "Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Aplastic Anemia, historical and forecasted epidemiology as well as the Aplastic Anemia market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Aplastic Anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Aplastic Anemia Market Forecast
https://www.delveinsight.com/report-store/aplastic-anemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Glaucoma Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight …
DelveInsight's "Glaucoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glaucoma Market Forecast
https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Glaucoma…
Familial Chylomicronemia Syndrome Market to Expand Significantly by 2034, States …
DelveInsight's "Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Familial Chylomicronemia Syndrome, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Familial Chylomicronemia Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Familial Chylomicronemia Syndrome…
Generalized Anxiety Disorder Pipeline 2025: Therapies, MOA Insights, and Key Cli …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Generalized Anxiety Disorder pipeline constitutes 12+ key companies continuously working towards developing 15+ Generalized Anxiety Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Generalized Anxiety Disorder Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Generalized Anxiety…
More Releases for Uveitis
Uveitis Market : An Overview Report
Introduction:
Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye. It can lead to vision impairment or even blindness if left untreated. Uveitis is categorized into different types, including anterior, intermediate, posterior, and panuveitis, depending on the part of the eye affected. The condition can be caused by infections, autoimmune diseases, or trauma. With increasing cases of autoimmune disorders and infectious diseases, the prevalence of uveitis…
Uveitis Treatment Market Size, Share | Trend 2030
Exclusive Report by Ameco Research: Uveitis Treatment Market Size Projected to Reach USD 2 Billion by 2030, Growing at 6% CAGR
Ameco Research is proud to announce the launch of its latest market research report, Uveitis Treatment Market. This comprehensive report provides in-depth analysis and insights into the current market trends and future projections in the Industry/Market Segment. Ameco Research has been at the forefront of providing quality market research…
Uveitis - Drug Pipeline Landscape, 2022
New York, Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of…
Uveitis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of uveitis based…
Japan Industry Statistics of Uveitis Treatment
Global Uveitis Treatment Market: Overview
Uveitis, an autoimmune eye disease, is considered rare for just around 38 in 100,000 people are afflicted by it. Because of this, it is often overlooked. Patients afflicted by uveitis are often referred to an expert after much delay on account of less awareness about the eye malady. This delays timely diagnosis and results in irreversible damage to various ocular structures.
Read Report Overview: https://www.transparencymarketresearch.com/uveitis-treatment-market.html
As per Cochrane,…
Uveitis Treatment Market Analysis of Top industry Scenario
Global Uveitis Treatment Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables).
According to a new report published by Allied Market Research, titled, "Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy &…
